ImmunoPET Partnership Potential CellSight's suite of immunoPET tracers, including VisAcT and the [18F]F-AraG activated T cell probe, backed by regulatory-ready eIND approvals, positions the company to attract co-development, licensing, or strategic partnerships with immuno-oncology programs.

Outsourced Radiochemistry Services As a very small team, CellSight could scale with contract radiochemistry, GMP tracer production, and regulatory support to accelerate IND-enabling work for pharma and biotech partners.

Repeated Imaging Advantage The GSV1-tk reporter gene with the [18F]FHBG PET probe enables repeated imaging to monitor cell therapy migration, proliferation and survival, offering longitudinal readouts that can shorten trial timelines and improve decision making.

Early Biotech Access Target small to mid-size IO-focused biotechs seeking novel PET tracers and companion diagnostics, providing early access to imaging data and support for regulatory pathways via flexible collaboration models.

Partnership Expansion Leverage CellSight's prior collaborations with Boehringer Ingelheim and Telix to approach additional global pharma partners for licensing, co-development, or distribution deals around VisAcT and related imaging technologies.